Home > BIGG > Search result

    Results: 2

    Italian clinical practice guidelines on cholangiocarcinoma Part I: classification, diagnosis and staging

    Alvaro, Domenico; Hassan, Cesare; Carpino, Guido; Fabris, Luca; Gringeri, Enrico; Granata, Vincenza; Mutignani, Massimiliano; Morement, Helen; Guglielmi, Alfredo; Ridola, Lorenzo; Marzioni, Marco; Grazi, Gianluca; Guido, Maria; Cardinale, Vincenzo; Giuliante, Felice; Giulio, Emilio Di; Tonini, Giuseppe; Pantano, Francesco; Venere, Rosanna; Bragazzi, Maria Consiglia; Biancanello, Francesca; Faccioli, Jessica; Giannetti, Aurora; Cintolo, Marcello; Giunta, Michela Di; Gambato, Martina; Lasagni, Alberto; Izzo, Francesco; Avallone, Antonio; Banales, Jesus; Rossi, Massimo; Laghi, Andrea; D'amati, Giulia; Mancino, Maria Grazia; Ridola, Lorenzo; Catalano, Carlo.
    Dig. liver dis; 55 (11), 2020
    Cholangiocarcinoma (CCA) is the second most common primary liver cancer, characterized by a poor prognosis and resistance to chemotherapeutics. The progressive increase in CCA incidence and mortality registered worldwide in the last two decades and the need to clarify various aspects of clinical manageme...
    Cholangiocarcinoma/diagnosis, Cholangiocarcinoma/classification, Cholangiocarcinoma/prevention & control, Pharmaceutical Preparations, Germ-Line Mutation/genetics
    Fulltext

    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

    Miller, R. E; Leary, A; Scott, C. L; Serra, V; Lord , C. J; Bowtell, D; Chang, D. K; Garsed, D. W; Jonkers, J; Ledermann, J. A; Nik-Zainal, S; Ray-Coquard, I; Shah, S. P; Matias-Guiu, X; Swisher, E. M; Yates, L. R.
    The European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group identified that there is currently uncertainty within the oncology community surrounding the different methods for HRD testing in HGSC. To address this, a collaborative project was launched with a...
    Homologous Recombination/genetics, Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use, Biomarkers, Genital Neoplasms, Female/diagnosis, Germ-Line Mutation/genetics
    Fulltext